03/13/23 7:00 AMNasdaq : BRTX fda approvallow floatBioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies,RHEA-AIvery positive
03/07/23 6:30 AMNasdaq : BRTX conferenceslow floatBioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35 th AnnualRHEA-AIneutral
03/02/23 7:30 AMNasdaq : BRTX low floatBioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® ProgramBioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:RHEA-AIvery positive
02/08/23 9:00 AMNasdaq : BRTX low floatBioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® ProgramBioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or theRHEA-AIneutral
12/06/22 7:00 AMNasdaq : BRTX low floatBioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an IndicationBioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), aRHEA-AIpositive
12/05/22 7:00 AMNasdaq : BRTX low floatBioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc DiseaseBioRestorative Therapies, Inc. (“BioRestorative” or the “Company” ) (NASDAQ : BRTX ), a clinical stage company focused on stem cell-basedRHEA-AIvery positive
11/29/22 11:20 AMNasdaq : BRTX conferenceslow floatBioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City. Event RHK Capital Disruptive Growth ConferenceRHEA-AIneutral
11/16/22 8:56 AMNasdaq : BRTX conferenceslow floatBioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHKRHEA-AIneutral
10/20/22 9:30 AMNasdaq : BRTX low floatBioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio ShowBioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk RadioRHEA-AIneutral
09/28/22 7:00 AMNasdaq : BRTX conferenceslow floatBioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth ConferenceBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7 th AnnualRHEA-AIneutral